Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CompumedicsASX:CMP 52 Capex-to-Operating-Cash-Flow is 1.19 as of Dec. 2025, which is 1% below its 10-year median of 1.20. GuruFocus rates ASX:CMP with a GF Score™ of 52/100 and a GF Value™ of A$0.32 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 431 Medical Devices & Instruments companies, Compumedics ranks worse than 85.38% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Compumedics Capex-to-Operating-Cash-Flow Related Terms
Compumedics Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Compumedics's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMP vs ABT, SYK, MDT: Capex-to-Operating-Cash-Flow Comparison
For the Medical Devices subindustry, Compumedics's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics Capex-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Compumedics's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 1.19 mean?
Compumedics (ASX:CMP) has a Capex-to-Operating-Cash-Flow of 1.19 as of Dec. 2025. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Compumedics and its competitors. This is near median its historical median of 1.20. Over the past decade, Compumedics' Capex-to-Operating-Cash-Flow has ranged from 0.69 to 89.96. According to the industry distribution chart, Compumedics ranks #368 out of 431 companies in the Medical Devices & Instruments industry, placing it in the top 85.4%.
Is Compumedics' Capex-to-Operating-Cash-Flow too high?
Compumedics' current Capex-to-Operating-Cash-Flow of 1.19 is near median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 89.96. The Medical Devices & Instruments industry median Capex-to-Operating-Cash-Flow is 0.41. Compumedics' value of 1.19 is 190.2% above this industry median. Based on the distribution chart, Compumedics ranks #368 out of 431 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Compumedics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Capex-to-Operating-Cash-Flow compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #368 out of 431 companies for Capex-to-Operating-Cash-Flow. This places Compumedics in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.41. Compumedics' value of 1.19 is 190.2% above this benchmark. Historically, Compumedics' own Capex-to-Operating-Cash-Flow has ranged from 0.69 to 89.96 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 0.41, Compumedics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Medical Devices & Instruments company?
The median Capex-to-Operating-Cash-Flow among Medical Devices & Instruments companies is 0.41, based on 431 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current Capex-to-Operating-Cash-Flow of 1.19 is 190.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median Capex-to-Operating-Cash-Flow is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current Capex-to-Operating-Cash-Flow is 1.19, which is near median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.32, compared to a current price of A$0.23 — trading 29.7% below its estimated fair value. The current Capex-to-Operating-Cash-Flow is 1.19, which is near median its 10-year median of 1.20 and 190.2% above the Medical Devices & Instruments industry median of 0.41. Compumedics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Capex-to-Operating-Cash-Flow is 1.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.23 is trading 29.7% below its estimated GF Value™ of A$0.32.
GuruFocus considers Compumedics to be Possible Value Trap.
Key valuation signals for ASX:CMP:
Capex-to-Operating-Cash-Flow: 1.19 (near median its 10-year median of 1.20)
GF Value™: A$0.32 vs. price of A$0.23 (29.7% below fair value)
Industry Position: 190.2% above the Medical Devices & Instruments median (#368 of 431)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
52GF Score
Get the complete analysis for ASX:CMP
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
